Longevity
Longevity has evolved rapidly in recent decades, garnering significant attention. From Shinya Yamanaka’s groundbreaking discovery in 2007 of reversing adult cells to embryonic stem cells, to the identification of the hallmarks of aging, the field has made remarkable strides.
Additionally, the World Health Organization’s classification of aging as a disease marks a pivotal shift in our understanding. With the advent of novel therapeutics and cutting-edge diagnostics, our perception of aging—and our approaches to it—are poised to transform dramatically.
As Chief Visionary Officer of the Regenerative Medicine Institute (RMI), Dr. Ricardo Rosselló is at the forefront of a groundbreaking effort to extend healthy human lifespan through cutting-edge cellular therapeutics. Before he was Governor, Rosselló had 15 years of research experience focused on tissue regeneration (Rosselló 2009), stem cell reprogramming, and the vocal learning pathway in the human brain.
By harnessing the power of stem cells and other regenerative technologies, RMI is working to combat the root causes of aging and age-related disease.
RMI has developed a comprehensive suite of treatments designed to address the hallmarks of aging at the genomic, cellular, and systemic levels. These include stem cell collection and storage, stem cell infusions, plasmapheresis, and targeted therapies for orthopedic, aesthetic, sexual wellness, and neurocognitive health. RMI’s innovative approach combines lifestyle interventions, regenerative medicine, and personalized care to optimize each patient’s unique “bio-blueprint” for longevity.
The results have been remarkable. Through a rigorous third-party study, RMI has demonstrated the ability to significantly slow the pace of biological aging in its patients compared to a control group of healthy individuals. With over 1000 patients treated, a robust research pipeline, and plans for international expansion, RMI is poised to revolutionize the field of longevity medicine.
